Market News & Trends
GeneCentric Therapeutics Appoints New CBO; Advances Drug Development Platform
GeneCentric Therapeutics, Inc. recently announced the appointments of Walter M. Capone as Chief Business Officer and Ellen Lubman to the company’s Board of Directors. In…
Celyad Obtains Additional US Patent for Cancer Treatment Based on TCR-Deficient Allogeneic CAR-T cells
Celyad recently announced the issuance of United States Patent No. 9,663,763 relating to Celyad’s method of treating cancer by administering allogeneic primary human T cells…
Cambrex Invests in New Capacity & Continuous Flow Technology
Cambrex Corporation recently announced it has expanded large-scale manufacturing capacity at its cGMP facility in Karlskoga, Sweden, and has introduced additional continuous flow manufacturing for…
Lubrizol Invests $60 Million to Expand Particle Sciences, Vesta & Other Facilities
The Lubrizol Corporation recently announced its LifeSciences business continues to invest in its key capabilities through a variety of planned expansions. During this latest phase,…
Envigo Announces Successful AAALAC Accreditation
Envigo has announced that its Research Models and Services (RMS) facility in Hyderabad, India, has been granted full accreditation by the Association for Assessment and…
KaloBios Submits IND Application to FDA
KaloBios Pharmaceuticals, Inc. recently announced it has submitted an Investigational New Drug (IND) application to the US FDA for benznidazole for the treatment of Chagas…
Bayer Receives FDA Approval of myBETAapp & BETACONNECT Navigator
Bayer recently announced that the US FDA has approved a supplemental Biologics License Application (sBLA) for myBETAapp and the BETACONNECT Navigator. With this software in…
Acasti Pharma & CordenPharma Announce Large-Scale Production of CaPre With Continuous Manufacturing
Acasti Pharma Inc. recently announced the achievement of a major corporate milestone by manufacturing the first cGMP batches of CaPre®, Acasti’s omega-3 pharmaceutical product candidate,…
Acasti Pharma & CordenPharma Announce Large-Scale Production of CaPre With Continuous Manufacturing
Acasti Pharma Inc. recently announced the achievement of a major corporate milestone by manufacturing the first cGMP batches of CaPre®, Acasti’s omega-3 pharmaceutical product candidate,…
Acasti Pharma & CordenPharma Announce Large-Scale Production of CaPre With Continuous Manufacturing
Acasti Pharma Inc. recently announced the achievement of a major corporate milestone by manufacturing the first cGMP batches of CaPre®, Acasti’s omega-3 pharmaceutical product candidate,…
Acasti Pharma & CordenPharma Announce Large-Scale Production of CaPre With Continuous Manufacturing
Acasti Pharma Inc. recently announced the achievement of a major corporate milestone by manufacturing the first cGMP batches of CaPre®, Acasti’s omega-3 pharmaceutical product candidate,…
Acasti Pharma & CordenPharma Announce Large-Scale Production of CaPre With Continuous Manufacturing
Acasti Pharma Inc. recently announced the achievement of a major corporate milestone by manufacturing the first cGMP batches of CaPre®, Acasti’s omega-3 pharmaceutical product candidate,…
Vetter & Microdermics Enter Into Strategic Agreement to Develop Innovative Microneedle Drug Delivery Systems
Vetter, a leading and innovative provider of aseptic prefilled drug delivery systems and Microdermics Inc., a Vancouver-based medical device company developing a novel hollow, metal…
Vetter & Microdermics Enter Into Strategic Agreement to Develop Innovative Microneedle Drug Delivery Systems
Vetter, a leading and innovative provider of aseptic prefilled drug delivery systems and Microdermics Inc., a Vancouver-based medical device company developing a novel hollow, metal…
Vetter & Microdermics Enter Into Strategic Agreement to Develop Innovative Microneedle Drug Delivery Systems
Vetter, a leading and innovative provider of aseptic prefilled drug delivery systems and Microdermics Inc., a Vancouver-based medical device company developing a novel hollow, metal…
Vetter & Microdermics Enter Into Strategic Agreement to Develop Innovative Microneedle Drug Delivery Systems
Vetter, a leading and innovative provider of aseptic prefilled drug delivery systems and Microdermics Inc., a Vancouver-based medical device company developing a novel hollow, metal…
Vetter & Microdermics Enter Into Strategic Agreement to Develop Innovative Microneedle Drug Delivery Systems
Vetter, a leading and innovative provider of aseptic prefilled drug delivery systems and Microdermics Inc., a Vancouver-based medical device company developing a novel hollow, metal…
Debiopharm Acquires Phase II Asset From ImmunoGen
Debiopharm International SA, part of Debiopharm Group, recently announced that it has acquired ImmunoGen’s IMGN529/DEBIO 1562, a clinical-stage anti-CD37 ADC for the treatment of patients…
OrphoMed Secures $39 Million
OrphoMed, Inc. recently announced the completion of a $39-million Series A financing. The round was led by New Enterprise Associates (NEA), and co-led by existing…
Teneobio & Poseida Announce License Agreement for the Use of UniDab in CAR T-Cell Therapy
Teneobio, Inc. and Poseida Therapeutics, Inc. recently announced they have entered a commercial license agreement for the use of Teneobio’s UniDabs, single-domain, human heavy chain…
